Related Experiment Video
Updated: Dec 23, 2025
23:06
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
19.5K
Multidrug-resistant tuberculosis care in the United States
A N Gobaud1, C A Haley2, J W Wilson3
1Rollins School of Public Health, Emory University, Atlanta, GA.
Summary
This study analyzed 1560 multidrug-resistant tuberculosis (MDR-TB) medical consultations from 2013-2017. Findings reveal key areas for enhanced medical training to improve MDR-TB patient care and treatment completion.
Area of Science:
- Public Health
- Infectious Diseases
- Medical Consultation Services
Background:
- The study aimed to assess the use of Tuberculosis (TB) Centers of Excellence (COE) consultation services.
- Evaluation focused on how these services supported patients with multidrug-resistant TB (MDR-TB).
Purpose of the Study:
- To examine the utilization patterns of the TB Centers of Excellence (COE) medical consultation service.
- To evaluate the application of these consultation services for patients diagnosed with multidrug-resistant TB (MDR-TB).
Main Methods:
- A secure database of medical consults was queried for MDR-TB cases between January 1, 2013, and December 31, 2017.
- Data analyzed included provider type, center, setting, year, and patient demographics (pediatric vs. adult).
- A random subgroup underwent thematic analysis to identify consultation topics.
Main Results:
- A total of 1560 MDR-TB consultation requests were received during the study period.
- Physicians accounted for the majority of consult requests (55%), primarily from public health departments (64%) for adult patients (80%).
- Key consultation themes included initial MDR-TB management, treatment complications, exposure management, and treatment completion.
Conclusions:
- Analysis of consultations offers insights into the expert advice provided for MDR-TB cases.
- Findings indicate specific areas where enhanced medical training and education could improve MDR-TB management practices and outcomes.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis V
473
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
473
01:29Pulmonary Tuberculosis I
745
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
745
01:26Pulmonary Tuberculosis IV
428
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
428
01:28Pulmonary Tuberculosis II
1.2K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.2K
01:31Pulmonary Tuberculosis III
806
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
806
01:29Therapeutic Drug Monitoring: Affecting Factors
130
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
130